Association between serum autotaxin or phosphatidylserine‐specific phospholipase A1 levels and melanoma

Autotaxin (ATX), a producing enzyme for lysophosphatidic acids, was first identified from the medium of a melanoma cell line and has been considered to be one of the candidate targets to treat melanoma; however, the association between serum ATX and melanoma in human subjects has not been elucidated...

Full description

Saved in:
Bibliographic Details
Published inJournal of dermatology Vol. 45; no. 5; pp. 571 - 579
Main Authors Kurano, Makoto, Miyagaki, Tomomitsu, Miyagawa, Takuya, Igarashi, Koji, Shimamoto, Satoshi, Ikeda, Hitoshi, Aoki, Junken, Sato, Shinichi, Yatomi, Yutaka
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.05.2018
Subjects
Online AccessGet full text
ISSN0385-2407
1346-8138
1346-8138
DOI10.1111/1346-8138.14278

Cover

Abstract Autotaxin (ATX), a producing enzyme for lysophosphatidic acids, was first identified from the medium of a melanoma cell line and has been considered to be one of the candidate targets to treat melanoma; however, the association between serum ATX and melanoma in human subjects has not been elucidated. Along with ATX, phosphatidylserine‐specific phospholipase A1 (PS‐PLA1) is a producing enzyme for lysophosphatidylserine, a similar glycero‐lysophospholipid mediator to lysophosphatidic acids. In the present study, we aimed to investigate the association between serum ATX or PS‐PLA1 levels and melanoma. We measured the serum levels of ATX, ATX isoforms and PS‐PLA1 in subjects with melanoma (n = 57) and healthy subjects (n = 58). We further investigated the existence of trends according to the clinical stages of melanoma. We observed that serum total ATX and classical ATX levels were significant higher and serum novel ATX levels tended to be higher in male subjects with melanoma, while no significant difference was observed between the two groups in female subjects. The trend test revealed that the serum total ATX and ATX isoforms were significantly associated with the clinical stages of female subjects with melanoma. Regarding PS‐PLA1, serum PS‐PLA1 levels were significantly higher in the melanoma subjects and associated with the clinical stages. The present study is the first study which revealed the association between ATX or PS‐PLA1 and melanoma, suggesting the possible involvement of ATX/lysophosphatidic acids or PS‐PLA1/lysophosphatidylserine axis in the pathogenesis of melanoma.
AbstractList Autotaxin (ATX), a producing enzyme for lysophosphatidic acids, was first identified from the medium of a melanoma cell line and has been considered to be one of the candidate targets to treat melanoma; however, the association between serum ATX and melanoma in human subjects has not been elucidated. Along with ATX, phosphatidylserine-specific phospholipase A1 (PS-PLA ) is a producing enzyme for lysophosphatidylserine, a similar glycero-lysophospholipid mediator to lysophosphatidic acids. In the present study, we aimed to investigate the association between serum ATX or PS-PLA levels and melanoma. We measured the serum levels of ATX, ATX isoforms and PS-PLA in subjects with melanoma (n = 57) and healthy subjects (n = 58). We further investigated the existence of trends according to the clinical stages of melanoma. We observed that serum total ATX and classical ATX levels were significant higher and serum novel ATX levels tended to be higher in male subjects with melanoma, while no significant difference was observed between the two groups in female subjects. The trend test revealed that the serum total ATX and ATX isoforms were significantly associated with the clinical stages of female subjects with melanoma. Regarding PS-PLA , serum PS-PLA levels were significantly higher in the melanoma subjects and associated with the clinical stages. The present study is the first study which revealed the association between ATX or PS-PLA and melanoma, suggesting the possible involvement of ATX/lysophosphatidic acids or PS-PLA /lysophosphatidylserine axis in the pathogenesis of melanoma.
Autotaxin ( ATX ), a producing enzyme for lysophosphatidic acids, was first identified from the medium of a melanoma cell line and has been considered to be one of the candidate targets to treat melanoma; however, the association between serum ATX and melanoma in human subjects has not been elucidated. Along with ATX , phosphatidylserine‐specific phospholipase A1 ( PS ‐ PLA 1 ) is a producing enzyme for lysophosphatidylserine, a similar glycero‐lysophospholipid mediator to lysophosphatidic acids. In the present study, we aimed to investigate the association between serum ATX or PS ‐ PLA 1 levels and melanoma. We measured the serum levels of ATX , ATX isoforms and PS ‐ PLA 1 in subjects with melanoma ( n = 57) and healthy subjects ( n = 58). We further investigated the existence of trends according to the clinical stages of melanoma. We observed that serum total ATX and classical ATX levels were significant higher and serum novel ATX levels tended to be higher in male subjects with melanoma, while no significant difference was observed between the two groups in female subjects. The trend test revealed that the serum total ATX and ATX isoforms were significantly associated with the clinical stages of female subjects with melanoma. Regarding PS ‐ PLA 1 , serum PS ‐ PLA 1 levels were significantly higher in the melanoma subjects and associated with the clinical stages. The present study is the first study which revealed the association between ATX or PS ‐ PLA 1 and melanoma, suggesting the possible involvement of ATX /lysophosphatidic acids or PS ‐ PLA 1 /lysophosphatidylserine axis in the pathogenesis of melanoma.
Autotaxin (ATX), a producing enzyme for lysophosphatidic acids, was first identified from the medium of a melanoma cell line and has been considered to be one of the candidate targets to treat melanoma; however, the association between serum ATX and melanoma in human subjects has not been elucidated. Along with ATX, phosphatidylserine‐specific phospholipase A1 (PS‐PLA1) is a producing enzyme for lysophosphatidylserine, a similar glycero‐lysophospholipid mediator to lysophosphatidic acids. In the present study, we aimed to investigate the association between serum ATX or PS‐PLA1 levels and melanoma. We measured the serum levels of ATX, ATX isoforms and PS‐PLA1 in subjects with melanoma (n = 57) and healthy subjects (n = 58). We further investigated the existence of trends according to the clinical stages of melanoma. We observed that serum total ATX and classical ATX levels were significant higher and serum novel ATX levels tended to be higher in male subjects with melanoma, while no significant difference was observed between the two groups in female subjects. The trend test revealed that the serum total ATX and ATX isoforms were significantly associated with the clinical stages of female subjects with melanoma. Regarding PS‐PLA1, serum PS‐PLA1 levels were significantly higher in the melanoma subjects and associated with the clinical stages. The present study is the first study which revealed the association between ATX or PS‐PLA1 and melanoma, suggesting the possible involvement of ATX/lysophosphatidic acids or PS‐PLA1/lysophosphatidylserine axis in the pathogenesis of melanoma.
Autotaxin (ATX), a producing enzyme for lysophosphatidic acids, was first identified from the medium of a melanoma cell line and has been considered to be one of the candidate targets to treat melanoma; however, the association between serum ATX and melanoma in human subjects has not been elucidated. Along with ATX, phosphatidylserine-specific phospholipase A1 (PS-PLA1 ) is a producing enzyme for lysophosphatidylserine, a similar glycero-lysophospholipid mediator to lysophosphatidic acids. In the present study, we aimed to investigate the association between serum ATX or PS-PLA1 levels and melanoma. We measured the serum levels of ATX, ATX isoforms and PS-PLA1 in subjects with melanoma (n = 57) and healthy subjects (n = 58). We further investigated the existence of trends according to the clinical stages of melanoma. We observed that serum total ATX and classical ATX levels were significant higher and serum novel ATX levels tended to be higher in male subjects with melanoma, while no significant difference was observed between the two groups in female subjects. The trend test revealed that the serum total ATX and ATX isoforms were significantly associated with the clinical stages of female subjects with melanoma. Regarding PS-PLA1 , serum PS-PLA1 levels were significantly higher in the melanoma subjects and associated with the clinical stages. The present study is the first study which revealed the association between ATX or PS-PLA1 and melanoma, suggesting the possible involvement of ATX/lysophosphatidic acids or PS-PLA1 /lysophosphatidylserine axis in the pathogenesis of melanoma.Autotaxin (ATX), a producing enzyme for lysophosphatidic acids, was first identified from the medium of a melanoma cell line and has been considered to be one of the candidate targets to treat melanoma; however, the association between serum ATX and melanoma in human subjects has not been elucidated. Along with ATX, phosphatidylserine-specific phospholipase A1 (PS-PLA1 ) is a producing enzyme for lysophosphatidylserine, a similar glycero-lysophospholipid mediator to lysophosphatidic acids. In the present study, we aimed to investigate the association between serum ATX or PS-PLA1 levels and melanoma. We measured the serum levels of ATX, ATX isoforms and PS-PLA1 in subjects with melanoma (n = 57) and healthy subjects (n = 58). We further investigated the existence of trends according to the clinical stages of melanoma. We observed that serum total ATX and classical ATX levels were significant higher and serum novel ATX levels tended to be higher in male subjects with melanoma, while no significant difference was observed between the two groups in female subjects. The trend test revealed that the serum total ATX and ATX isoforms were significantly associated with the clinical stages of female subjects with melanoma. Regarding PS-PLA1 , serum PS-PLA1 levels were significantly higher in the melanoma subjects and associated with the clinical stages. The present study is the first study which revealed the association between ATX or PS-PLA1 and melanoma, suggesting the possible involvement of ATX/lysophosphatidic acids or PS-PLA1 /lysophosphatidylserine axis in the pathogenesis of melanoma.
Author Miyagaki, Tomomitsu
Kurano, Makoto
Yatomi, Yutaka
Igarashi, Koji
Ikeda, Hitoshi
Sato, Shinichi
Miyagawa, Takuya
Shimamoto, Satoshi
Aoki, Junken
Author_xml – sequence: 1
  givenname: Makoto
  orcidid: 0000-0002-2596-1145
  surname: Kurano
  fullname: Kurano, Makoto
  email: kurano-tky@umin.ac.jp
  organization: The University of Tokyo
– sequence: 2
  givenname: Tomomitsu
  orcidid: 0000-0003-1879-3128
  surname: Miyagaki
  fullname: Miyagaki, Tomomitsu
  organization: The University of Tokyo
– sequence: 3
  givenname: Takuya
  surname: Miyagawa
  fullname: Miyagawa, Takuya
  organization: The University of Tokyo
– sequence: 4
  givenname: Koji
  surname: Igarashi
  fullname: Igarashi, Koji
  organization: TOSOH Corporation
– sequence: 5
  givenname: Satoshi
  surname: Shimamoto
  fullname: Shimamoto, Satoshi
  organization: TOSOH Corporation
– sequence: 6
  givenname: Hitoshi
  surname: Ikeda
  fullname: Ikeda, Hitoshi
  organization: The University of Tokyo
– sequence: 7
  givenname: Junken
  surname: Aoki
  fullname: Aoki, Junken
  organization: Tohoku University
– sequence: 8
  givenname: Shinichi
  surname: Sato
  fullname: Sato, Shinichi
  organization: The University of Tokyo
– sequence: 9
  givenname: Yutaka
  surname: Yatomi
  fullname: Yatomi, Yutaka
  email: yatoyuta-tky@umin.ac.jp
  organization: The University of Tokyo
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29500864$$D View this record in MEDLINE/PubMed
BookMark eNqFkb9OHDEQxi0EguOSOl1kKU2aBf9br7c8EUiCkGigtny-sTDatRd7F3JdHiHPmCfBxx0pkFDcjOT5fd-M5jtG-yEGQOgTJSe0vFPKhawU5eqECtaoPTT797OPZoSrumKCNEfoOOd7QlhbU3KIjkolREkxQ36Rc7TejD4GvITxCSDgDGnqsZnGOJpfPuCY8HAX83BXsNW6K20f4O_vP3kA6523u27s_GAy4AXFHTxCl7EJK9xDZ0LszQd04EzRftzVObq9OL85-1FdXX__eba4qqyQVFVghWgUlRwUNGAEV47VzC0dY6xxhNRK8JWTLVXguGKiXTonueRt27RgieNz9HXrO6T4MEEede-zha5sAXHKmhFKeMN58ZmjL2_Q-zilULYrFCc1k5KwQn3eUdOyh5Ueku9NWuvXIxag3gI2xZwTOG39-HLRMRnfaUr0Jiy9iUZvotEvYRXd6Rvdq_X7it2kJ9_B-n-4vvx2vtU9A1X2pWU
CitedBy_id crossref_primary_10_1177_09612033221128494
crossref_primary_10_1038_s41598_021_85595_7
crossref_primary_10_1111_1756_185X_13689
crossref_primary_10_1016_j_tranon_2021_101237
crossref_primary_10_1507_endocrj_EJ18_0451
crossref_primary_10_2183_pjab_94_025
crossref_primary_10_1007_s10555_018_9729_x
crossref_primary_10_1248_bpb_b22_00001
crossref_primary_10_1016_j_plipres_2021_101112
crossref_primary_10_3390_ijms24086986
crossref_primary_10_1016_j_cca_2020_01_011
crossref_primary_10_1016_j_pharmthera_2023_108415
crossref_primary_10_1016_j_cca_2020_06_019
crossref_primary_10_1111_1744_9987_14211
crossref_primary_10_1016_j_plipres_2020_101068
crossref_primary_10_1038_s41598_020_59590_3
crossref_primary_10_1038_s41598_022_08388_6
crossref_primary_10_1111_1756_185X_14031
crossref_primary_10_14712_fb2023069050149
crossref_primary_10_1177_0004563218818197
crossref_primary_10_3390_ijms222312685
Cites_doi 10.1016/j.prostaglandins.2009.04.009
10.1016/j.bbacli.2015.08.003
10.1158/1541-7786.MCR-14-0263
10.4061/2011/194857
10.1111/j.1365-2141.2008.07325.x
10.1016/0014-5793(93)81724-E
10.1016/j.bbagen.2016.11.032
10.1093/jb/mvr126
10.1038/nrc1143
10.1074/jbc.M111.276725
10.1194/jlr.P072090
10.1084/jem.20141827
10.1016/S0014-5793(97)00098-7
10.1016/j.yexcr.2014.11.010
10.1021/acs.jmedchem.6b01270
10.1038/nmeth.2172
10.1186/1476-4598-9-140
10.1006/bbrc.1996.0127
10.1194/jlr.P071803
10.1016/S1388-1981(02)00134-8
10.1007/s10555-011-9319-7
10.1016/j.canlet.2014.10.001
10.1038/nsmb.1980
10.1074/jbc.274.16.11053
10.1016/S0021-9258(18)45911-X
10.5551/jat.25650
10.1371/journal.pone.0130074
10.1016/j.cca.2007.10.005
10.1093/jb/mvu077
10.1023/A:1020950420196
10.1136/bjo.2007.116947
10.1074/jbc.M206812200
10.1083/jcb.200204026
10.1016/j.cca.2010.04.006
10.1016/j.bbalip.2012.08.015
ContentType Journal Article
Copyright 2018 Japanese Dermatological Association
2018 Japanese Dermatological Association.
Copyright © 2018 Japanese Dermatological Association
Copyright_xml – notice: 2018 Japanese Dermatological Association
– notice: 2018 Japanese Dermatological Association.
– notice: Copyright © 2018 Japanese Dermatological Association
DBID AAYXX
CITATION
NPM
7T5
H94
K9.
7X8
DOI 10.1111/1346-8138.14278
DatabaseName CrossRef
PubMed
Immunology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList PubMed
CrossRef
AIDS and Cancer Research Abstracts
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1346-8138
EndPage 579
ExternalDocumentID 29500864
10_1111_1346_8138_14278
JDE14278
Genre article
Journal Article
GrantInformation_xml – fundername: JST/AMED
– fundername: AMED
– fundername: JSPS
  funderid: 16H06236
GroupedDBID ---
.3N
.55
.GA
.Y3
05W
0R~
10A
123
1OB
1OC
29K
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5HH
5LA
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAMMB
AAMNL
AANHP
AANLZ
AAONW
AAQQT
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEFGJ
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFFNX
AFFPM
AFGKR
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AHMBA
AIACR
AIDQK
AIDYY
AIQQE
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
B.R
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
CYRXZ
D-6
D-7
D-E
D-F
D-I
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EJD
EMB
EMOBN
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
R.K
RIWAO
ROL
RX1
SAMSI
SJN
SUPJJ
SV3
TEORI
UB1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WVDHM
WXI
WXSBR
X7M
XG1
ZZTAW
~IA
~WT
AAYXX
CITATION
AAHHS
ACCFJ
AEEZP
AEQDE
AEUQT
AFPWT
AIWBW
AJBDE
NPM
WRC
7T5
H94
K9.
7X8
ID FETCH-LOGICAL-c4618-ec4478163e8e7ea438f252fbf2227f005843df6918ef38249bff63639979ec0f3
IEDL.DBID DR2
ISSN 0385-2407
1346-8138
IngestDate Fri Sep 05 09:01:12 EDT 2025
Tue Oct 07 05:57:01 EDT 2025
Wed Feb 19 02:43:30 EST 2025
Thu Apr 24 22:54:53 EDT 2025
Wed Oct 01 03:43:53 EDT 2025
Thu Sep 25 07:35:38 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords lysophosphatidylserine
lysophosphatidic acids
melanoma
phosphatidylserine-specific phospholipase A1
autotaxin
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
2018 Japanese Dermatological Association.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4618-ec4478163e8e7ea438f252fbf2227f005843df6918ef38249bff63639979ec0f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ORCID 0000-0003-1879-3128
0000-0002-2596-1145
PMID 29500864
PQID 2030526602
PQPubID 1006353
PageCount 9
ParticipantIDs proquest_miscellaneous_2010373384
proquest_journals_2030526602
pubmed_primary_29500864
crossref_citationtrail_10_1111_1346_8138_14278
crossref_primary_10_1111_1346_8138_14278
wiley_primary_10_1111_1346_8138_14278_JDE14278
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate May 2018
PublicationDateYYYYMMDD 2018-05-01
PublicationDate_xml – month: 05
  year: 2018
  text: May 2018
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Tokyo
PublicationTitle Journal of dermatology
PublicationTitleAlternate J Dermatol
PublicationYear 2018
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2015; 13
2009; 89
2013; 1831
2017; 60
2015; 4
2002; 19
2002; 1582
2002; 158
1992; 267
2017; 1861
2002; 277
2015; 10
2011; 30
2007; 91
2008; 388
2008; 143
2011; 18
2011; 2011
2012; 151
1993; 316
1997; 404
2017; 58
2015; 157
2015; 356
2015; 333
2015; 212
2010; 411
1997; 57
2015; 22
1999; 274
2003; 3
1996; 218
2010; 9
2011; 286
2012; 9
e_1_2_10_23_1
e_1_2_10_24_1
e_1_2_10_21_1
e_1_2_10_22_1
e_1_2_10_20_1
e_1_2_10_2_1
e_1_2_10_4_1
e_1_2_10_18_1
e_1_2_10_3_1
e_1_2_10_19_1
e_1_2_10_6_1
e_1_2_10_16_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_8_1
e_1_2_10_14_1
e_1_2_10_37_1
e_1_2_10_7_1
e_1_2_10_15_1
e_1_2_10_36_1
Kawagoe H (e_1_2_10_10_1) 1997; 57
e_1_2_10_12_1
e_1_2_10_35_1
e_1_2_10_9_1
e_1_2_10_13_1
e_1_2_10_34_1
e_1_2_10_33_1
e_1_2_10_11_1
e_1_2_10_32_1
e_1_2_10_31_1
e_1_2_10_30_1
e_1_2_10_29_1
e_1_2_10_27_1
e_1_2_10_28_1
e_1_2_10_25_1
e_1_2_10_26_1
References_xml – volume: 1831
  start-page: 74
  year: 2013
  end-page: 85
  article-title: Role of the autotaxin‐lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy
  publication-title: Biochim Biophys Acta
– volume: 60
  start-page: 1309
  year: 2017
  end-page: 1324
  article-title: Highly potent non‐carboxylic acid autotaxin inhibitors reduce melanoma metastasis and chemotherapeutic resistance of breast cancer stem cells
  publication-title: J Med Chem
– volume: 58
  start-page: 433
  year: 2017
  end-page: 442
  article-title: Different origins of lysophospholipid mediators between coronary and peripheral arteries in acute coronary syndrome
  publication-title: J Lipid Res
– volume: 19
  start-page: 603
  year: 2002
  end-page: 608
  article-title: Expression of autotaxin (npp‐2) is closely linked to invasiveness of breast cancer cells
  publication-title: Clin Exp Metastasis
– volume: 57
  start-page: 2516
  year: 1997
  end-page: 2521
  article-title: Expression and transcriptional regulation of the pd‐ialpha/autotaxin gene in neuroblastoma
  publication-title: Cancer Res
– volume: 13
  start-page: 174
  year: 2015
  end-page: 185
  article-title: Autotaxin and lpa1 and lpa5 receptors exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis
  publication-title: Mol Cancer Res
– volume: 158
  start-page: 227
  year: 2002
  end-page: 233
  article-title: Autotaxin has lysophospholipase d activity leading to tumor cell growth and motility by lysophosphatidic acid production
  publication-title: J Cell Biol
– volume: 4
  start-page: 92
  year: 2015
  end-page: 98
  article-title: Blood levels of serotonin are specifically correlated with plasma lysophosphatidylserine among the glycero‐lysophospholipids
  publication-title: BBA Clin
– volume: 388
  start-page: 51
  year: 2008
  end-page: 58
  article-title: Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation
  publication-title: Clin Chim Acta
– volume: 151
  start-page: 89
  year: 2012
  end-page: 97
  article-title: Identification and biochemical characterization of a novel autotaxin isoform, atxdelta, with a four‐amino acid deletion
  publication-title: J Biochem
– volume: 267
  start-page: 2524
  year: 1992
  end-page: 2529
  article-title: Identification, purification, and partial sequence analysis of autotaxin, a novel motility‐stimulating protein
  publication-title: J Biol Chem
– volume: 3
  start-page: 582
  year: 2003
  end-page: 591
  article-title: The emerging role of lysophosphatidic acid in cancer
  publication-title: Nat Rev Cancer
– volume: 277
  start-page: 48737
  year: 2002
  end-page: 48744
  article-title: Serum lysophosphatidic acid is produced through diverse phospholipase pathways
  publication-title: J Biol Chem
– volume: 404
  start-page: 82
  year: 1997
  end-page: 86
  article-title: Nmd, a novel gene differentially expressed in human melanoma cell lines, encodes a new atypical member of the enzyme family of lipases
  publication-title: FEBS Lett
– volume: 274
  start-page: 11053
  year: 1999
  end-page: 11059
  article-title: An alternative splicing form of phosphatidylserine‐specific phospholipase a1 that exhibits lysophosphatidylserine‐specific lysophospholipase activity in humans
  publication-title: J Biol Chem
– volume: 316
  start-page: 1
  year: 1993
  end-page: 4
  article-title: Role of a serum phospholipase a1 in the phosphatidylserine‐induced t cell inhibition
  publication-title: FEBS Lett
– volume: 212
  start-page: 1011
  year: 2015
  end-page: 1020
  article-title: The lysophosphatidylserine receptor gpr174 constrains regulatory t cell development and function
  publication-title: J Exp Med
– volume: 1861
  start-page: 256
  year: 2017
  end-page: 263
  article-title: A rhodium(iii)‐based inhibitor of autotaxin with antiproliferative activity
  publication-title: Biochim Biophys Acta
– volume: 143
  start-page: 60
  year: 2008
  end-page: 70
  article-title: Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma
  publication-title: Br J Haematol
– volume: 9
  start-page: 140
  year: 2010
  article-title: Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid
  publication-title: Mol Cancer
– volume: 58
  start-page: 763
  year: 2017
  end-page: 771
  article-title: Analysis of glycero‐lysophospholipids in gastric cancerous ascites
  publication-title: J Lipid Res
– volume: 10
  start-page: e0130074
  year: 2015
  article-title: A new enzyme immunoassay for the quantitative determination of classical autotaxins (atxalpha, atxbeta, and atxgamma) and novel autotaxins (atxdelta and atxepsilon)
  publication-title: PLoS One
– volume: 157
  start-page: 81
  year: 2015
  end-page: 89
  article-title: Lysophosphatidic acid as a lipid mediator with multiple biological actions
  publication-title: J Biochem
– volume: 89
  start-page: 135
  year: 2009
  end-page: 139
  article-title: Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol
  publication-title: Prostaglandins Other Lipid Mediat
– volume: 286
  start-page: 34654
  year: 2011
  end-page: 34663
  article-title: Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells
  publication-title: J Biol Chem
– volume: 30
  start-page: 557
  year: 2011
  end-page: 565
  article-title: Autotaxin and lpa receptor signaling in cancer
  publication-title: Cancer Metastasis Rev
– volume: 9
  start-page: 1021
  year: 2012
  end-page: 1029
  article-title: Tgfalpha shedding assay: an accurate and versatile method for detecting gpcr activation
  publication-title: Nat Methods
– volume: 411
  start-page: 1090
  year: 2010
  end-page: 1094
  article-title: A novel enzyme immunoassay for the determination of phosphatidylserine‐specific phospholipase a(1) in human serum samples
  publication-title: Clin Chim Acta
– volume: 2011
  start-page: 194857
  year: 2011
  article-title: Autotaxin: its role in biology of melanoma cells and as a pharmacological target
  publication-title: Enzyme Res
– volume: 18
  start-page: 198
  year: 2011
  end-page: 204
  article-title: Structural basis of substrate discrimination and integrin binding by autotaxin
  publication-title: Nat Struct Mol Biol
– volume: 356
  start-page: 589
  year: 2015
  end-page: 596
  article-title: The src homology 3 binding domain is required for lysophosphatidic acid 3 receptor‐mediated cellular viability in melanoma cells
  publication-title: Cancer Lett
– volume: 218
  start-page: 714
  year: 1996
  end-page: 719
  article-title: Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells
  publication-title: Biochem Biophys Res Commun
– volume: 22
  start-page: 518
  year: 2015
  end-page: 526
  article-title: Lysophosphatidylserine has bilateral effects on macrophages in the pathogenesis of atherosclerosis
  publication-title: J Atheroscler Thromb
– volume: 91
  start-page: 1385
  year: 2007
  end-page: 1392
  article-title: Reduced expression of autotaxin predicts survival in uveal melanoma
  publication-title: Br J Ophthalmol
– volume: 333
  start-page: 183
  year: 2015
  end-page: 189
  article-title: New insights into the autotaxin/lpa axis in cancer development and metastasis
  publication-title: Exp Cell Res
– volume: 1582
  start-page: 26
  year: 2002
  end-page: 32
  article-title: Structure and function of phosphatidylserine‐specific phospholipase a1
  publication-title: Biochim Biophys Acta
– ident: e_1_2_10_21_1
  doi: 10.1016/j.prostaglandins.2009.04.009
– ident: e_1_2_10_33_1
  doi: 10.1016/j.bbacli.2015.08.003
– ident: e_1_2_10_12_1
  doi: 10.1158/1541-7786.MCR-14-0263
– ident: e_1_2_10_15_1
  doi: 10.4061/2011/194857
– ident: e_1_2_10_11_1
  doi: 10.1111/j.1365-2141.2008.07325.x
– ident: e_1_2_10_35_1
  doi: 10.1016/0014-5793(93)81724-E
– ident: e_1_2_10_17_1
  doi: 10.1016/j.bbagen.2016.11.032
– ident: e_1_2_10_30_1
  doi: 10.1093/jb/mvr126
– ident: e_1_2_10_5_1
  doi: 10.1038/nrc1143
– ident: e_1_2_10_32_1
  doi: 10.1074/jbc.M111.276725
– ident: e_1_2_10_23_1
  doi: 10.1194/jlr.P072090
– ident: e_1_2_10_37_1
  doi: 10.1084/jem.20141827
– ident: e_1_2_10_24_1
  doi: 10.1016/S0014-5793(97)00098-7
– ident: e_1_2_10_8_1
  doi: 10.1016/j.yexcr.2014.11.010
– ident: e_1_2_10_16_1
  doi: 10.1021/acs.jmedchem.6b01270
– ident: e_1_2_10_22_1
  doi: 10.1038/nmeth.2172
– ident: e_1_2_10_13_1
  doi: 10.1186/1476-4598-9-140
– ident: e_1_2_10_29_1
  doi: 10.1006/bbrc.1996.0127
– ident: e_1_2_10_34_1
  doi: 10.1194/jlr.P071803
– ident: e_1_2_10_19_1
  doi: 10.1016/S1388-1981(02)00134-8
– volume: 57
  start-page: 2516
  year: 1997
  ident: e_1_2_10_10_1
  article-title: Expression and transcriptional regulation of the pd‐ialpha/autotaxin gene in neuroblastoma
  publication-title: Cancer Res
– ident: e_1_2_10_6_1
  doi: 10.1007/s10555-011-9319-7
– ident: e_1_2_10_14_1
  doi: 10.1016/j.canlet.2014.10.001
– ident: e_1_2_10_31_1
  doi: 10.1038/nsmb.1980
– ident: e_1_2_10_25_1
  doi: 10.1074/jbc.274.16.11053
– ident: e_1_2_10_4_1
  doi: 10.1016/S0021-9258(18)45911-X
– ident: e_1_2_10_36_1
  doi: 10.5551/jat.25650
– ident: e_1_2_10_28_1
  doi: 10.1371/journal.pone.0130074
– ident: e_1_2_10_27_1
  doi: 10.1016/j.cca.2007.10.005
– ident: e_1_2_10_3_1
  doi: 10.1093/jb/mvu077
– ident: e_1_2_10_9_1
  doi: 10.1023/A:1020950420196
– ident: e_1_2_10_18_1
  doi: 10.1136/bjo.2007.116947
– ident: e_1_2_10_20_1
  doi: 10.1074/jbc.M206812200
– ident: e_1_2_10_2_1
  doi: 10.1083/jcb.200204026
– ident: e_1_2_10_26_1
  doi: 10.1016/j.cca.2010.04.006
– ident: e_1_2_10_7_1
  doi: 10.1016/j.bbalip.2012.08.015
SSID ssj0029510
Score 2.2674608
Snippet Autotaxin (ATX), a producing enzyme for lysophosphatidic acids, was first identified from the medium of a melanoma cell line and has been considered to be one...
Autotaxin ( ATX ), a producing enzyme for lysophosphatidic acids, was first identified from the medium of a melanoma cell line and has been considered to be...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 571
SubjectTerms Acids
autotaxin
Enzymes
Isoforms
lysophosphatidic acids
lysophosphatidylserine
Melanoma
Phosphatidylserine
phosphatidylserine‐specific phospholipase A1
Phospholipase A1
Serum levels
Title Association between serum autotaxin or phosphatidylserine‐specific phospholipase A1 levels and melanoma
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2F1346-8138.14278
https://www.ncbi.nlm.nih.gov/pubmed/29500864
https://www.proquest.com/docview/2030526602
https://www.proquest.com/docview/2010373384
Volume 45
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library - Core collection (SURFmarket)
  issn: 0385-2407
  databaseCode: DR2
  dateStart: 20060101
  customDbUrl:
  isFulltext: true
  eissn: 1346-8138
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0029510
  providerName: Wiley-Blackwell
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA7iQbz4fqwvInjw0qVtsm16FN1FBD2IgreSJy5222XbgnryJ_gb_SVm-sIHIuKtkAxNM4_MdL6ZIHTkM0Ui6WrHsEg61FNW5wRVjrIE2ieUiBptcRWc39KLu0GLJoRamLo_RPfDDTSjsteg4FzkH5TcIzRwmEeYVXY_hHJfjwRVUHXdNZDywX-o8ghsAHmEsGnuA1ieL_Sfz6VvzuZn37U6fEbLSLTLrjEnD_2yEH35_KWj47--awUtNa4pPqllaRXN6XQNLVw2yfd1NP7AStzgu7CV4HKCeVlkBX8cpzib4el9lk_v7TT1lORVdeHbyytUdAIqqRnNkvHUnp_4xMMJwJZyzFOFJzrhaTbhG-h2NLw5PXeamxocSQOPOVpSKFkNiGY61JwSZvyBb4SBSlsDVxdSokwQeUwbwmzEJ4wJCDhHYaSla8gmmk-zVG8jrEJOjRtIl4aKUhFB5TC1lkVaw2SYCHuo3_Iplk0bc7hNI4nbcAY2MIYNjKsN7KHjjmBad_D4eepey_i4UeU89sEkWjfG9XvosBu2SgiZFZ7qrIQ5UG5po33aQ1u1wHTvsjIIcaMdqdn-2yLii7Nh9bDzV4JdtGgXwmo45h6aL2al3rcuUyEOKq14B5vgCcA
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9tAEB4VKpVeaEsfpKV0kThwcWR7N_b6iFpQSkkOVSJxs-x9iKiOHRFbAk78hP7G_pLO2I4VqKqq4mZpd-31zmO_2XkswKEvNY-UaxwrI-UIT6PMpUI7GgcYnwueNtEW42A4FWcXg4u1XJimPkR34EaSUetrEnA6kF6Tco-LwJEelyjtfig34KkI0FohYPS9KyHlE4KoPQlyQJ6EsC3vQ9E8D15wf2f6A27eR6_19nP6AtRq4k3UyY9-VaZ9dfugpuPj_uwlbLfolB037PQKnph8B56NWv_7a5itUZO1IV4Mmbias6QqizK5nuWsuGKLy2K5uMRu-iZb1gmGv-5-UlInBSa1rUU2W-AWyo49llHk0pIluWZzkyV5MU_ewPT0ZPJ56LSXNThKBJ50jBKUtRpwI01oEsGl9Qe-TS0l21q6vVBwbYPIk8ZyiUZfam3ACR-FkVGu5W9hMy9yswtMh4mwbqBcEWoh0oiShwUqF4W6yco07EF_RahYtZXM6UKNLF5ZNLSAMS1gXC9gD466AYumiMffu-6tKB-30ryMfdKKiGRcvwcHXTPKITlXktwUFfWhjEs0-EUP3jUc030LmZBMR2xp6P6vScRnX07qh_f_O-ATbA0no_P4_Ov42wd4jpOSTXTmHmyWV5X5iAiqTPdrEfkNVAIN4Q
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NatwwEB6aFEIu_U_rNm1UyCEXL7Yl2_IxdLOkSbuUkoW9GVs_7BKvbWIb2p76CH3GPkk1ttfspoRScjNIWms1-kYznm9GAMcelzQSjrI1j4TNXGkwlzJpSzNAeZTRtGNbTIPzGbuY-_ONXJiuPsTwwQ2R0eprBLgqpd5AuUtZYHOXcoN2L-Q78JD5EUda3_jrUELKQwuijSRwHyMJYV_eB9k8t35g-2T6y9zctl7b42fyGMR64h3r5HrU1OlI_LhV0_F-_-wJPOqtU3Labaen8EDlz2Dvcx9_fw7LDWmSnuJFzCZuViRp6qJOvi1zUtyQclFU5cJ0k9-zqk0w_P3zFyZ1IjGpby2yZWmOUHLqkgyZSxVJcklWKkvyYpW8gNnk7OrDud1f1mALFrjcVoJh1mpAFVehShjl2vM9nWpMttV4eyGjUgeRy5Wm3Dh9qdYBRfsojJRwND2A3bzI1SsgMkyYdgLhsFAylkaYPMyMchFGN2mehhaM1oKKRV_JHC_UyOK1R4MLGOMCxu0CWnAyDCi7Ih53dz1cSz7u0VzFHmpFY8k4ngXvh2aDQwyuJLkqGuyDGZfG4WcWvOx2zPAuswnRdTQtndz_NYn4YnzWPrz-3wFHsPdlPIk_fZxevoF9MyfekTMPYbe-adRbY0DV6bsWIX8A5wENZQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+between+serum+autotaxin+or+phosphatidylserine%E2%80%90specific+phospholipase+A1+levels+and+melanoma&rft.jtitle=Journal+of+dermatology&rft.au=Kurano%2C+Makoto&rft.au=Miyagaki%2C+Tomomitsu&rft.au=Miyagawa%2C+Takuya&rft.au=Igarashi%2C+Koji&rft.date=2018-05-01&rft.issn=0385-2407&rft.eissn=1346-8138&rft.volume=45&rft.issue=5&rft.spage=571&rft.epage=579&rft_id=info:doi/10.1111%2F1346-8138.14278&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_1346_8138_14278
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0385-2407&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0385-2407&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0385-2407&client=summon